Collegium Pharmaceutical (NASDAQ:COLL) Stock Rating Lowered by StockNews.com

StockNews.com downgraded shares of Collegium Pharmaceutical (NASDAQ:COLL) from a strong-buy rating to a buy rating in a report published on Wednesday morning.

COLL has been the subject of a number of other reports. Needham & Company LLC reiterated a buy rating and issued a $40.00 price target on shares of Collegium Pharmaceutical in a research report on Thursday, April 11th. Truist Financial upped their target price on shares of Collegium Pharmaceutical from $37.00 to $40.00 and gave the stock a buy rating in a report on Monday, February 26th. Piper Sandler reissued an overweight rating and set a $39.00 price target (up from $37.00) on shares of Collegium Pharmaceutical in a report on Friday, February 23rd. Finally, Jefferies Financial Group reaffirmed a hold rating and issued a $37.00 price objective (up previously from $30.00) on shares of Collegium Pharmaceutical in a research note on Thursday, January 4th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of Moderate Buy and a consensus price target of $39.00.

Collegium Pharmaceutical Stock Performance

NASDAQ:COLL opened at $37.51 on Wednesday. The firm has a market capitalization of $1.23 billion, a price-to-earnings ratio of 31.79 and a beta of 1.06. The company has a debt-to-equity ratio of 2.48, a current ratio of 1.17 and a quick ratio of 1.10. The business has a fifty day moving average price of $37.56 and a 200-day moving average price of $31.77. Collegium Pharmaceutical has a one year low of $20.83 and a one year high of $40.95.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings results on Thursday, February 22nd. The specialty pharmaceutical company reported $1.45 EPS for the quarter, topping analysts’ consensus estimates of $1.20 by $0.25. Collegium Pharmaceutical had a return on equity of 107.39% and a net margin of 8.50%. The business had revenue of $149.75 million during the quarter, compared to analysts’ expectations of $147.66 million. Sell-side analysts forecast that Collegium Pharmaceutical will post 5.63 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Pacer Advisors Inc. lifted its position in shares of Collegium Pharmaceutical by 68.4% in the fourth quarter. Pacer Advisors Inc. now owns 2,174,718 shares of the specialty pharmaceutical company’s stock worth $66,938,000 after buying an additional 883,380 shares in the last quarter. SummerHaven Investment Management LLC raised its holdings in shares of Collegium Pharmaceutical by 1.1% during the 4th quarter. SummerHaven Investment Management LLC now owns 34,034 shares of the specialty pharmaceutical company’s stock worth $1,048,000 after acquiring an additional 368 shares in the last quarter. Natixis Advisors L.P. boosted its position in shares of Collegium Pharmaceutical by 152.9% during the 3rd quarter. Natixis Advisors L.P. now owns 54,359 shares of the specialty pharmaceutical company’s stock valued at $1,215,000 after acquiring an additional 32,865 shares during the last quarter. Loomis Sayles & Co. L P grew its holdings in shares of Collegium Pharmaceutical by 32.7% in the third quarter. Loomis Sayles & Co. L P now owns 273,628 shares of the specialty pharmaceutical company’s stock valued at $6,116,000 after purchasing an additional 67,439 shares in the last quarter. Finally, Everence Capital Management Inc. bought a new stake in Collegium Pharmaceutical in the fourth quarter worth $302,000.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.